BerGenBio reports 43% response rate with bemcentinib monotherapy in AXL positive R/R AML/MDS patients at ASH
· 43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14) · Phase II trial continues in combination with chemotherapeutics in first line AML · Bemcentinib with decitabine cohort has completed recruitment, data will be submitted for presentation at upcoming medical congressBergen, Norway, 3 Dec 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, today announced that it presented a